AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19789937 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments (control group)
Number of subjects: 18
Study 19367427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nurse-led clinic
Number of subjects: 200
Study 19367427 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 200
Study 17693685 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose (DEX)
Number of subjects: 7
Study 17693685 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid/alcohol-modified cornstarch (MAMS)
Number of subjects: 7
Study 17693685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study 15189092 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory phase (days 21 to 28 of the cycle)
Number of subjects: 7
Study 15189092 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase (days 7 to 14 of the cycle)
Number of subjects: 7
Study 11825173 — intervention group
Group type: EXPERIMENTAL
Intervention: SNOMED-RT
Number of subjects: 2022
Study 11825173 — intervention group
Group type: COMPARATOR
Intervention: ICD9-CM
Number of subjects: 2022
Study 9563139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month depot (3.75 mg leuprorelin acetate)
Number of subjects: 42
Study 9563139 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month depot (11.25 mg leuprorelin acetate)
Number of subjects: 42
Study 7885968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (1-2 g every 8-12 hours)
Number of subjects: 0
Study 7885968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 0
Study 3199913 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM clinical intervention
Number of subjects: 842
Study 3199913 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM telephone intervention
Number of subjects: 842
Study 3199913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination clinical/telephone interventions
Number of subjects: 842
Study 3199913 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 842
Study 31910819 — intervention group
Group type: COMPARATOR
Intervention: Nutritional intervention encouraging consumption of unprocessed and minimally processed foods and physical activities; three individualized nutritional counselling sessions.
Number of subjects: 300
Study 31910819 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 300
Study 30947693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2210
Study 27686283 — intervention group
Group type: EXPERIMENTAL
Intervention: BioNet's aP vaccine
Number of subjects: 60
Study 27686283 — intervention group
Group type: EXPERIMENTAL
Intervention: BioNet's TdaP vaccine
Number of subjects: 60
Study 27686283 — intervention group
Group type: COMPARATOR
Intervention: Adacel® vaccine
Number of subjects: 60
Study 27686283 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 60
Study 27686283 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects
Number of subjects: 60
Study 26093979 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1-1 week
Number of subjects: 1009
Study 26093979 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1-2 weeks
Number of subjects: 1009
Study 26093979 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1-4 weeks
Number of subjects: 1009
Study 26093979 — intervention group
Group type: COMPARATOR
Intervention: bOPV-4 weeks
Number of subjects: 1009
Study 23638799 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy (HD) - 4 servings of dairy per day
Number of subjects: 23
Study 23638799 — intervention group
Group type: COMPARATOR
Intervention: Low dairy (LD) - no more than 2 servings of dairy per day
Number of subjects: 23
Study 20607595 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 80
Study 19743978 — intervention group
Group type: COMPARATOR
Intervention: Paediatric feed (PF)
Number of subjects: 25
Study 19743978 — intervention group
Group type: COMPARATOR
Intervention: Adult feed (AF)
Number of subjects: 25
Study 19743978 — intervention group
Group type: EXPERIMENTAL
Intervention: Older children's feed (OCF)
Number of subjects: 25
Study 17606237 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality TV cosmetic surgery program (The Swan)
Number of subjects: 147
Study 17606237 — intervention group
Group type: COMPARATOR
Intervention: Reality TV home improvement program (Clean Sweep)
Number of subjects: 147
Study 14681341 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg single oral dose
Number of subjects: 23
Study 14681341 — intervention group
Group type: COMPARATOR
Intervention: Etoricoxib in patients with advanced renal disease
Number of subjects: 23
Study 11360159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily
Number of subjects: 44
Study 11360159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 11360159 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine after placebo (S/P)
Number of subjects: 44
Study 11360159 — intervention group
Group type: COMPARATOR
Intervention: Placebo after Sibutramine (P/S)
Number of subjects: 44
Study 10078796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up care program
Number of subjects: 597
Study 10078796 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 597
Study 7917739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐4) u. ml‐1
Number of subjects: 30
Study 7917739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐2) u. ml‐1
Number of subjects: 30
Study 7917739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐1) u. ml‐1
Number of subjects: 30
Study 7917739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin 10(0) u. ml‐1
Number of subjects: 30
Study 7917739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin 10(‐3) to 10(‐1) u. ml‐1
Number of subjects: 30
Study 7917739 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin (various concentrations)
Number of subjects: 30
Study 7917739 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.9% saline
Number of subjects: 30
Study 3293456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (80 mg/kg each Monday and Thursday during external radiation therapy)
Number of subjects: 296
Study 3293456 — intervention group
Group type: COMPARATOR
Intervention: Misonidazole (1 gm/m2 in the same schedule, not to exceed 12 gm/m2)
Number of subjects: 296
Study 3293456 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 296
Study 3293456 — intervention group
Group type: COMPARATOR
Intervention: Misonidazole
Number of subjects: 296
Study 3293456 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 296
Study 31832749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoscopic lung volume reduction (BLVR) procedures (valves, coils, thermal vapor ablation)
Number of subjects: 138
Study 31832749 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of patients not eligible for BLVR)
Number of subjects: 138
Study 29696684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (100 mg BID for 24 weeks, increased to 150 mg BID for nonresponders after 4 weeks)
Number of subjects: 150
Study 29696684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 29696684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Number of subjects: 150
Study 28741744 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal Suit (T‐Balance®)
Number of subjects: 100
Study 28741744 — intervention group
Group type: COMPARATOR
Intervention: Conventional cotton clothes (Control)
Number of subjects: 100
Study 26653203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing (4 oral-fluid self-test kits at enrolment, additional kits on request)
Number of subjects: 350
Study 26653203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing
Number of subjects: 350
Study 26653203 — intervention group
Group type: COMPARATOR
Intervention: Standard-care (routine clinic-based testing)
Number of subjects: 350
Study 24023320 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU vitamin D‐3
Number of subjects: 36
Study 21435332 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure + Response Prevention (no safety behaviours)
Number of subjects: 44
Study 21435332 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure + Safety Behaviours (cleaning hands with a hygienic wipe)
Number of subjects: 44
Study 21435332 — intervention group
Group type: COMPARATOR
Intervention: No-Intervention Control Group
Number of subjects: 44
Study 18192839 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEIs (Angiotensin-Converting Enzyme Inhibitors) administered for 6 weeks
Number of subjects: 509
Study 16704648 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound product (Dovobet/Daivobet/Taclonex) for 52 weeks
Number of subjects: 634
Study 16704648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating group (two-compound product and calcipotriol for 52 weeks)
Number of subjects: 634
Study 16704648 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol for 48 weeks after 4 weeks of the two-compound product
Number of subjects: 634
Study 16704648 — intervention group
Group type: COMPARATOR
Intervention: Two-compound product vs Calcipotriol
Number of subjects: 634
Study 16704648 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound product
Number of subjects: 634
Study 16704648 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating group
Number of subjects: 634
Study 16704648 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol group
Number of subjects: 634
Study 15581966 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC) using high-dose cisplatin alone (140-250 mg/m2) or high-dose cisplatin plus mitomycin C (7 mg/m2), pepleomycin (7 mg/m2) and 5-fluorouracil (700 mg/m2)
Number of subjects: 23
Study 10945313 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 5 mg felodipine
Number of subjects: 12
Study 10945313 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Number of subjects: 12
Study 10945313 — intervention group
Group type: COMPARATOR
Intervention: Water with 5 mg felodipine
Number of subjects: 12
Study 10945313 — intervention group
Group type: COMPARATOR
Intervention: Water with 2.5 mg felodipine for 2 days followed by 5 mg felodipine for 6 days
Number of subjects: 12
Study 9323507 — intervention group
Group type: EXPERIMENTAL
Intervention: CWB: continuous warm blood cardioplegia
Number of subjects: 60
Study 9323507 — intervention group
Group type: EXPERIMENTAL
Intervention: ICB: intermittent cold blood with warm blood controlled reperfusion
Number of subjects: 60
Study 9323507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryst: intermittent cold crystalloid cardioplegia
Number of subjects: 60
Study 8405008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 5 mg/day (Group 1)
Number of subjects: 34
Study 8405008 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day (Group 2)
Number of subjects: 34
Study 8405008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (both groups)
Number of subjects: 34
Study 3633503 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch (TT)
Number of subjects: 60
Study 3633503 — intervention group
Group type: COMPARATOR
Intervention: Placebo simulation of TT
Number of subjects: 60
Study 30219475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of M. officinalis (HEMO) (700 mg/d)
Number of subjects: 70
Study 30219475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 30219475 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic extract of M. officinalis (HEMO)
Number of subjects: 70
Study 30219475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 25747955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg omega-3 fatty acid supplements (containing 180 mg eicosapentaenoic acid and 120 mg docosahexanoic acid)
Number of subjects: 56
Study 25747955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25517587 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational reinforcement by researchers and technical staff members
Number of subjects: 60
Study 25517587 — intervention group
Group type: COMPARATOR
Intervention: No motivational reinforcement
Number of subjects: 60
Study 22813682 — intervention group
Group type: EXPERIMENTAL
Intervention: GWL+SWA
Number of subjects: 197
Study 22813682 — intervention group
Group type: EXPERIMENTAL
Intervention: GWL
Number of subjects: 197
Study 22813682 — intervention group
Group type: EXPERIMENTAL
Intervention: SWA
Number of subjects: 197
Study 22813682 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 197
Study 20063120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + chemotherapy
Number of subjects: 3163
Study 20063120 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 3163
Study 18710420 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylometazoline
Number of subjects: 12
Study 18710420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16396000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric approach to assess noninferiority
Number of subjects: 0
Study 16396000 — intervention group
Group type: COMPARATOR
Intervention: Parametric or semiparametric methods
Number of subjects: 0
Study 14622039 — intervention group
Group type: EXPERIMENTAL
Intervention: Respect Not Risk Firearm Safety Lesson
Number of subjects: 433
Study 10942228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LDAC), 10 mg/m2 subcutaneously twice a day for 21 days every 2 months until relapse.
Number of subjects: 86
Study 10942228 — intervention group
Group type: COMPARATOR
Intervention: Observation (no additional therapy).
Number of subjects: 86
Study 10942228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine (LDAC).
Number of subjects: 86
Study 8932271 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully matched for 17 DRB1 specificities
Number of subjects: 74
Study 8932271 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 74
Study 8932271 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched group (fully compatible)
Number of subjects: 74
Study 8932271 — intervention group
Group type: COMPARATOR
Intervention: Mismatched group
Number of subjects: 74
Study 1578935 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic BMT
Number of subjects: 96
Study 1578935 — intervention group
Group type: COMPARATOR
Intervention: Autologous BMT
Number of subjects: 96
Study 1578935 — intervention group
Group type: COMPARATOR
Intervention: Prolonged intensive chemotherapy
Number of subjects: 96
Study 1578935 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensification (HDAra-C+amsacrine or IDAra-C+mitoxantrone followed by vincristine+adriamycin+cyclophosphamide and etoposide+Ara-C)
Number of subjects: 96
Study 1578935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease-free survival (DFS)
Number of subjects: 96
Study 3922936 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1 or 2 g intramuscular injections for ten days)
Number of subjects: 36
Study 31699946 — intervention group
Group type: EXPERIMENTAL
Intervention: Renogen (biosimilar EPO)
Number of subjects: 45
Study 31699946 — intervention group
Group type: COMPARATOR
Intervention: Eprex (originator EPO)
Number of subjects: 45
Study 29193747 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg cherry-flavored mini lozenge
Number of subjects: 43
Study 29193747 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg cherry-flavored mini lozenge
Number of subjects: 43
Study 29193747 — intervention group
Group type: COMPARATOR
Intervention: 2 mg mint-flavored mini lozenge
Number of subjects: 43
Study 29193747 — intervention group
Group type: COMPARATOR
Intervention: 4 mg mint-flavored mini lozenge
Number of subjects: 43
Study 26354927 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine/lomustine/vincristine (PCV) chemotherapy
Number of subjects: 139
Study 26354927 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing (NGS)
Number of subjects: 139
Study 26354927 — intervention group
Group type: COMPARATOR
Intervention: 1p/19q codeleted tumors
Number of subjects: 139
Study 23761303 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 1 mg
Number of subjects: 180
Study 23761303 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 2.5 mg
Number of subjects: 180
Study 23761303 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg
Number of subjects: 180
Study 23761303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 22176842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fax to Quit plus Enhanced Academic Detailing (F2Q+EAD)
Number of subjects: 49
Study 22176842 — intervention group
Group type: COMPARATOR
Intervention: Fax to Quit‐Only (F2Q‐Only)
Number of subjects: 49
Study 19952950 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interferon-alpha 2a
Number of subjects: 850
Study 17505437 — intervention group
Group type: EXPERIMENTAL
Intervention: TISSEEL VH S/D
Number of subjects: 100
Study 17505437 — intervention group
Group type: COMPARATOR
Intervention: TISSEEL VH
Number of subjects: 100
Study 16177249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of azithromycin orally
Number of subjects: 328
Study 16177249 — intervention group
Group type: COMPARATOR
Intervention: 2.4 million units of penicillin G benzathine intramuscularly
Number of subjects: 328
Study 11929348 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC) 50/100microg, administered twice daily via inhaler for 12 weeks
Number of subjects: 0
Study 11929348 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100microg, administered twice daily via inhaler for 12 weeks
Number of subjects: 0
Study 11929348 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 0
Study 11929348 — intervention group
Group type: COMPARATOR
Intervention: FP
Number of subjects: 0
Study 9683114 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour incontinence care schedule
Number of subjects: 0
Study 9683114 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour incontinence care schedule
Number of subjects: 0
Study 9683114 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence care intervention
Number of subjects: 0
Study 8006262 — intervention group
Group type: COMPARATOR
Intervention: Monophasic waveform
Number of subjects: 21
Study 8006262 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 21
Study 2842140 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 2842140 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31712950 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation
Number of subjects: 22
Study 31712950 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 22
Study 28604133 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cetirizine 1%
Number of subjects: 85
Study 28604133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 26892849 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitisation and reprocessing (EMDR) therapy (12 hours total: 3×60 min planning/preparation followed by 6×90 min desensitisation/reprocessing)
Number of subjects: 72
Study 26892849 — intervention group
Group type: COMPARATOR
Intervention: Stabilisation therapy (12 hours total: 12×60 min)
Number of subjects: 72
Study 24188252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 20
Study 24188252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23842081 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-fat from mountain-pasture grazing cows (G)
Number of subjects: 38
Study 23842081 — intervention group
Group type: COMPARATOR
Intervention: Conventional Danish butter (C)
Number of subjects: 38
Study 21731996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine with midazolam (3 mL 0.5% bupivacaine and 0.4 mL (2 mg) midazolam)
Number of subjects: 100
Study 21731996 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine without midazolam (3 mL 0.5% bupivacaine with 0.4 mL saline)
Number of subjects: 100
Study 19362014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen blocker
Number of subjects: 48
Study 19362014 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt blocker
Number of subjects: 48
Study 19362014 — intervention group
Group type: COMPARATOR
Intervention: Left double-lumen tube (DLT)
Number of subjects: 48
Study 19362014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen blocker (left bronchus occlusion)
Number of subjects: 48
Study 19362014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen blocker (right bronchus occlusion)
Number of subjects: 48
Study 19362014 — intervention group
Group type: EXPERIMENTAL
Intervention: All blockers
Number of subjects: 48
Study 19362014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen blocker and Arndt blocker
Number of subjects: 48
Study 19362014 — intervention group
Group type: COMPARATOR
Intervention: DLT
Number of subjects: 48
Study 17081282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trace element supplements (copper 2.5 to 3.1 mg/day, selenium 315 to 380 µg/day, zinc 26.2 to 31.4 mg/day) for 8 to 21 days
Number of subjects: 41
Study 17081282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 17081282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous trace element supplements
Number of subjects: 41
Study 15471833 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐labeled ethylene dicysteine (EC) C225 administered before 20 mg test dose
Number of subjects: 6
Study 15471833 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐labeled ethylene dicysteine (EC) C225 administered after 400 mg/m2 loading dose of unlabeled C225
Number of subjects: 6